<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url>
      <loc>https://www.ophthalmologytimes.com/view/oculis-phase-3-diamond-trials-miss-vision-endpoints-in-diabetic-macular-edema</loc><lastmod>2026-06-02T15:53:50.240Z</lastmod><news:news><news:publication_date>2026-06-02T15:53:50.240Z</news:publication_date>
        <news:title><![CDATA[Oculis phase 3 DIAMOND trials miss vision endpoints in diabetic macular edema]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/tearsolutions-advances-lacripep-into-phase-2-following-dual-fda-designations-in-neurotrophic-keratitis</loc><lastmod>2026-06-02T13:00:00Z</lastmod><news:news><news:publication_date>2026-06-02T13:00:00Z</news:publication_date>
        <news:title><![CDATA[TearSolutions advances Lacripep into phase 2 following dual FDA designations in neurotrophic keratitis]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/opuviz-aflibercept-europe-retinal-diseases</loc><lastmod>2026-06-02T11:00:00Z</lastmod><news:news><news:publication_date>2026-06-02T11:00:00Z</news:publication_date>
        <news:title><![CDATA[Opuviz aflibercept biosimilar launches in Europe for retinal diseases]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/study-links-alcohol-consumption-to-earlier-advanced-presbyopia-in-men</loc><lastmod>2026-06-02T10:00:00Z</lastmod><news:news><news:publication_date>2026-06-02T10:00:00Z</news:publication_date>
        <news:title><![CDATA[Study links alcohol consumption to earlier advanced presbyopia in men]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/neuroop-guru-stopping-glp-1-therapy-may-trigger-recurrent-papilledema-in-iih-cases</loc><lastmod>2026-06-02T04:00:00Z</lastmod><news:news><news:publication_date>2026-06-02T04:00:00Z</news:publication_date>
        <news:title><![CDATA[NeuroOp Guru: Stopping GLP-1 therapy may trigger recurrent papilledema in IIH cases]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/demodex-blepharitis-in-surgical-patients-for-ocular-surface-optimization</loc><lastmod>2026-06-01T16:30:00Z</lastmod><news:news><news:publication_date>2026-06-01T16:30:00Z</news:publication_date>
        <news:title><![CDATA[Practical strategies: Managing Demodex blepharitis in surgical patients for ocular surface optimization]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/corneal-biomechanics-and-deep-learning-a-new-approach-to-keratoconus-detection</loc><lastmod>2026-06-01T15:00:00Z</lastmod><news:news><news:publication_date>2026-06-01T15:00:00Z</news:publication_date>
        <news:title><![CDATA[Corneal biomechanics and deep learning: A new approach to keratoconus detection]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/outlook-therapeutics-resubmits-bla-for-bevacizumab-vikg-ons-5010-lytenava-</loc><lastmod>2026-06-01T14:48:15.077Z</lastmod><news:news><news:publication_date>2026-06-01T14:48:15.077Z</news:publication_date>
        <news:title><![CDATA[Outlook Therapeutics resubmits BLA for bevacizumab-vikg (ONS-5010/LYTENAVA)]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/diagnostic-imaging-in-retinal-vascular-disease-management</loc><lastmod>2026-06-01T12:05:00Z</lastmod><news:news><news:publication_date>2026-06-01T12:05:00Z</news:publication_date>
        <news:title><![CDATA[Diagnostic Imaging in Retinal Vascular Disease Management]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/advancing-care-across-retinal-vascular-diseases</loc><lastmod>2026-06-01T12:00:00Z</lastmod><news:news><news:publication_date>2026-06-01T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Advancing Care Across Retinal Vascular Diseases]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/pregnancy-a-window-of-opportunity-to-assess-bodily-ocular-health</loc><lastmod>2026-06-01T10:00:00Z</lastmod><news:news><news:publication_date>2026-06-01T10:00:00Z</news:publication_date>
        <news:title><![CDATA[Pregnancy: a window of opportunity to assess bodily/ocular health]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/thn391-enters-phase-1b-trial-for-diabetic-macular-edema</loc><lastmod>2026-05-28T17:58:11.058Z</lastmod><news:news><news:publication_date>2026-05-28T17:58:11.058Z</news:publication_date>
        <news:title><![CDATA[THN391 enters phase 1b trial for diabetic macular edema]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/balance-ophthalmics-receives-fda-510-k-clearance-for-wireless-enabled-nocturnal-iop-device</loc><lastmod>2026-05-28T13:00:00Z</lastmod><news:news><news:publication_date>2026-05-28T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Balance Ophthalmics receives FDA 510(k) clearance for wireless-enabled nocturnal IOP device]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/contaminated-trypan-blue-fungal-endophthalmitis-outbreak-cataract-surgery</loc><lastmod>2026-05-28T11:00:00Z</lastmod><news:news><news:publication_date>2026-05-28T11:00:00Z</news:publication_date>
        <news:title><![CDATA[Contaminated trypan blue solution linked to fungal endophthalmitis outbreak after cataract surgery]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/visiting-the-doctor-in-a-foreign-land</loc><lastmod>2026-05-27T16:00:00Z</lastmod><news:news><news:publication_date>2026-05-27T16:00:00Z</news:publication_date>
        <news:title><![CDATA[Visiting the doctor in a foreign land]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/preclinical-study-explores-contact-lens-based-neuromodulation-for-depression</loc><lastmod>2026-05-27T10:00:00Z</lastmod><news:news><news:publication_date>2026-05-27T10:00:00Z</news:publication_date>
        <news:title><![CDATA[Preclinical study explores contact lens–based neuromodulation for depression]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/fda-appeal-bevacizumab-vikg-bla-neovascular-amd</loc><lastmod>2026-05-26T21:56:46.746Z</lastmod><news:news><news:publication_date>2026-05-26T21:56:46.746Z</news:publication_date>
        <news:title><![CDATA[FDA grants appeal for bevacizumab-vikg BLA in neovascular AMD]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/spinach-derived-nanoparticles-restore-corneal-antioxidants-in-dry-eye-models</loc><lastmod>2026-05-26T14:09:47.610Z</lastmod><news:news><news:publication_date>2026-05-26T14:09:47.610Z</news:publication_date>
        <news:title><![CDATA[Spinach-derived nanoparticles restore corneal antioxidants in dry eye models]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/bausch-lomb-launches-preservision-areds3-adding-b-vitamin-complex-to-areds2-form</loc><lastmod>2026-05-26T12:55:30.422Z</lastmod><news:news><news:publication_date>2026-05-26T12:55:30.422Z</news:publication_date>
        <news:title><![CDATA[Bausch + Lomb launches PreserVision AREDS3]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/rising-star-introducing-adam-jacobson-md</loc><lastmod>2026-05-23T10:00:00Z</lastmod><news:news><news:publication_date>2026-05-23T10:00:00Z</news:publication_date>
        <news:title><![CDATA[Rising Star: Introducing Adam Jacobson, MD]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/transient-visual-loss-linked-to-elevated-cardiovascular-and-stroke-risk-for-up-to-a-decade</loc><lastmod>2026-05-22T10:00:00Z</lastmod><news:news><news:publication_date>2026-05-22T10:00:00Z</news:publication_date>
        <news:title><![CDATA[Transient visual loss linked to elevated cardiovascular and stroke risk for up to a decade]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/when-to-escalate-glaucoma-treatment-key-lessons-from-three-complex-cases</loc><lastmod>2026-05-21T20:00:00Z</lastmod><news:news><news:publication_date>2026-05-21T20:00:00Z</news:publication_date>
        <news:title><![CDATA[When to escalate glaucoma treatment: Key lessons from three complex cases]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/post-lasik-corneas-subclinical-nerve-deficits-altered-immune-cell-behavior</loc><lastmod>2026-05-21T20:00:00Z</lastmod><news:news><news:publication_date>2026-05-21T20:00:00Z</news:publication_date>
        <news:title><![CDATA[Post-LASIK corneas show subclinical nerve deficits and altered immune cell behavior years after surgery]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/tinlarebant-earns-swiss-orphan-drug-status-for-stargardt-disease</loc><lastmod>2026-05-20T15:49:12.573Z</lastmod><news:news><news:publication_date>2026-05-20T15:49:12.573Z</news:publication_date>
        <news:title><![CDATA[Tinlarebant earns Swiss orphan drug status for Stargardt disease]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/a-case-of-blepharospasm-relieved-by-playing-an-oboe-and-singing</loc><lastmod>2026-05-20T10:00:00Z</lastmod><news:news><news:publication_date>2026-05-20T10:00:00Z</news:publication_date>
        <news:title><![CDATA[A case of blepharospasm relieved by playing an oboe and singing]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/eyespy-consults-a-decision-support-app-to-improve-neuro-ophthalmology-consult-confidence</loc><lastmod>2026-05-19T15:05:49.923Z</lastmod><news:news><news:publication_date>2026-05-19T15:05:49.923Z</news:publication_date>
        <news:title><![CDATA[EyeSpy Consults: A decision-support app to improve neuro-ophthalmology consult confidence ]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/qa102-treatment-intermediate-dry-amd</loc><lastmod>2026-05-19T10:00:00Z</lastmod><news:news><news:publication_date>2026-05-19T10:00:00Z</news:publication_date>
        <news:title><![CDATA[How QA102's oral mechanism could reshape treatment for intermediate dry AMD]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/biogen-completes-acquisition-of-apellis-pharmaceuticals</loc><lastmod>2026-05-18T15:33:17.365Z</lastmod><news:news><news:publication_date>2026-05-18T15:33:17.365Z</news:publication_date>
        <news:title><![CDATA[Biogen completes acquisition of Apellis Pharmaceuticals]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/arvo-2026-using-ai-to-analyze-pediatric-ultra-widevfield-fundus-images</loc><lastmod>2026-05-18T15:29:43.231Z</lastmod><news:news><news:publication_date>2026-05-18T15:29:43.231Z</news:publication_date>
        <news:title><![CDATA[ARVO 2026: Using AI to analyze pediatric ultra-wide field fundus images]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/effects-of-short-term-topical-or-systemic-corticosteroids-on-iop</loc><lastmod>2026-05-17T10:00:00Z</lastmod><news:news><news:publication_date>2026-05-17T10:00:00Z</news:publication_date>
        <news:title><![CDATA[Effects of short-term topical or systemic corticosteroids on IOP]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/laparoscopic-sleeve-gastrectomy-positively-affects-ocular-transparency</loc><lastmod>2026-05-16T16:30:00Z</lastmod><news:news><news:publication_date>2026-05-16T16:30:00Z</news:publication_date>
        <news:title><![CDATA[Laparoscopic sleeve gastrectomy positively affects ocular transparency ]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/arvo-2026-retinal-neuroprotective-role-of-cav1</loc><lastmod>2026-05-16T10:00:00Z</lastmod><news:news><news:publication_date>2026-05-16T10:00:00Z</news:publication_date>
        <news:title><![CDATA[ARVO 2026: Retinal neuroprotective role of Cav1]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/mco-010-retinal-specialists-patients</loc><lastmod>2026-05-15T16:30:00Z</lastmod><news:news><news:publication_date>2026-05-15T16:30:00Z</news:publication_date>
        <news:title><![CDATA[How MCO-010's 3-year data are redefining what's possible for advanced retinal degeneration]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/arvo-2026-3d-imaging-and-deep-learning-for-retinal-disease</loc><lastmod>2026-05-15T10:00:00Z</lastmod><news:news><news:publication_date>2026-05-15T10:00:00Z</news:publication_date>
        <news:title><![CDATA[ARVO 2026: 3D imaging and deep learning for retinal disease]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/arvo-2026-mildred-weisenfeld-award-winner-nisha-acharya-md-on-big-data-trials-and-vision-preservation</loc><lastmod>2026-05-14T21:30:00Z</lastmod><news:news><news:publication_date>2026-05-14T21:30:00Z</news:publication_date>
        <news:title><![CDATA[ARVO 2026: Mildred Weisenfeld Award winner Nisha Acharya, MD, on big data, trials, and vision preservation]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/intracortical-visual-prosthesis-a-new-chapter-in-advancing-visual-restoration</loc><lastmod>2026-05-14T16:53:42.639Z</lastmod><news:news><news:publication_date>2026-05-14T16:53:42.639Z</news:publication_date>
        <news:title><![CDATA[Intracortical visual prosthesis: A new chapter in advancing visual restoration ]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/avacincaptad-pegol-ga-treatment-driving-vision</loc><lastmod>2026-05-14T14:30:00Z</lastmod><news:news><news:publication_date>2026-05-14T14:30:00Z</news:publication_date>
        <news:title><![CDATA[Avacincaptad pegol analysis links GA treatment to preserved driving vision]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/arvo-2026-global-retfound-study</loc><lastmod>2026-05-14T10:00:00Z</lastmod><news:news><news:publication_date>2026-05-14T10:00:00Z</news:publication_date>
        <news:title><![CDATA[ARVO 2026: Global RETFound study]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/arvo-2026-corneal-nerve-metrics-with-cellchek-c</loc><lastmod>2026-05-13T21:30:00Z</lastmod><news:news><news:publication_date>2026-05-13T21:30:00Z</news:publication_date>
        <news:title><![CDATA[ARVO 2026: Corneal nerve metrics with CellChek C]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/arvo-2026-anti-inflammatory-agents-and-refractive-development-in-children</loc><lastmod>2026-05-13T10:00:00Z</lastmod><news:news><news:publication_date>2026-05-13T10:00:00Z</news:publication_date>
        <news:title><![CDATA[ARVO 2026: Anti-inflammatory agents and refractive development in children]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/arvo-2026-optogenetic-remain-3-year-study-data</loc><lastmod>2026-05-12T21:30:00Z</lastmod><news:news><news:publication_date>2026-05-12T21:30:00Z</news:publication_date>
        <news:title><![CDATA[ARVO 2026: Optogenetic REMAIN 3 year study data]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/no-smoking-gun-oct-biomarker-found-for-dme-outcomes-insights-from-protocol-t</loc><lastmod>2026-05-12T14:59:32.559Z</lastmod><news:news><news:publication_date>2026-05-12T14:59:32.559Z</news:publication_date>
        <news:title><![CDATA[No 'smoking gun' OCT biomarker found for DME outcomes: Insights from Protocol T]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/arvo-2026-cogan-award-recipients-reflect-on-career-and-award</loc><lastmod>2026-05-12T10:00:00Z</lastmod><news:news><news:publication_date>2026-05-12T10:00:00Z</news:publication_date>
        <news:title><![CDATA[ARVO 2026: Cogan Award recipients reflect on career and award]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/beyond-the-gut-understanding-gender-disparities-and-ocular-complications-in-inflammatory-bowel-disease</loc><lastmod>2026-05-11T14:20:23.664Z</lastmod><news:news><news:publication_date>2026-05-11T14:20:23.664Z</news:publication_date>
        <news:title><![CDATA[Beyond the gut: Understanding gender disparities and ocular complications in inflammatory bowel disease]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/arvo-2026-diet-and-its-affect-on-amd-progression</loc><lastmod>2026-05-11T12:33:47.725Z</lastmod><news:news><news:publication_date>2026-05-11T12:33:47.725Z</news:publication_date>
        <news:title><![CDATA[ARVO 2026: Diet and its affect on AMD progression]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/beep-baseball-for-the-blind-and-visually-impaired-where-s-the-beep-</loc><lastmod>2026-05-10T12:38:00Z</lastmod><news:news><news:publication_date>2026-05-10T12:38:00Z</news:publication_date>
        <news:title><![CDATA[Beep Baseball for the blind and visually impaired: Where’s the Beep?]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/phase-3-trial-positive-topline-results-for-elegrobart-for-the-treatment-of-ted</loc><lastmod>2026-05-09T12:00:00Z</lastmod><news:news><news:publication_date>2026-05-09T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Phase 3 trial: Positive topline results for elegrobart for the treatment of TED]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/qa102-data-intermediate-dry-amd-drusen</loc><lastmod>2026-05-18T17:23:20.345Z</lastmod><news:news><news:publication_date>2026-05-08T19:30:55.918Z</news:publication_date>
        <news:title><![CDATA[QA102 data suggest signal in intermediate dry AMD, but insignificant drusen volume change]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/study-low-dose-eye-drops-manage-adult-myopia-for-24-hours</loc><lastmod>2026-05-08T18:30:00Z</lastmod><news:news><news:publication_date>2026-05-08T18:30:00Z</news:publication_date>
        <news:title><![CDATA[Study: Low-dose eye drops manage adult myopia for 24 hours ]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/laru-zova-visual-function-improvements-xlrp-gene-therapy</loc><lastmod>2026-05-07T20:45:32.849Z</lastmod><news:news><news:publication_date>2026-05-07T20:45:32.849Z</news:publication_date>
        <news:title><![CDATA[Laru-zova sustains visual function improvements at 12 months in XLRP gene therapy trial]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/arvo-2026-ai-screening-for-psychological-distress-in-glaucoma-clinics</loc><lastmod>2026-05-07T12:40:11.091Z</lastmod><news:news><news:publication_date>2026-05-07T12:40:11.091Z</news:publication_date>
        <news:title><![CDATA[ARVO 2026: AI screening for psychological distress in glaucoma clinics]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/arvo-2026-vamikibart-trials-advance-il-6-inhibition-in-retinal-disease</loc><lastmod>2026-05-06T18:00:00Z</lastmod><news:news><news:publication_date>2026-05-06T18:00:00Z</news:publication_date>
        <news:title><![CDATA[ARVO 2026: Vamikibart trials advance IL-6 inhibition in retinal disease]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/atsn-201-advances-to-registrational-trial-for-x-linked-retinoschisis</loc><lastmod>2026-05-06T15:13:46.058Z</lastmod><news:news><news:publication_date>2026-05-06T15:13:46.058Z</news:publication_date>
        <news:title><![CDATA[ATSN-201 advances to registrational trial for X-linked retinoschisis]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/arvo-2026-scalable-pipeline-for-data-extraction-from-ophthalmic-clinical-letters</loc><lastmod>2026-05-06T00:00:00Z</lastmod><news:news><news:publication_date>2026-05-06T00:00:00Z</news:publication_date>
        <news:title><![CDATA[ARVO 2026: Scalable pipeline for data extraction from ophthalmic clinical letters]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/durability-and-dual-targeting-push-retinal-therapy-beyond-the-anti-vegf-baseline</loc><lastmod>2026-05-05T23:00:00Z</lastmod><news:news><news:publication_date>2026-05-05T23:00:00Z</news:publication_date>
        <news:title><![CDATA[ARVO 2026: Durability and dual targeting push retinal therapy beyond the anti-VEGF baseline]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/arvo-2026-the-natural-history-of-thyroid-eye-disease</loc><lastmod>2026-05-05T17:26:08.629Z</lastmod><news:news><news:publication_date>2026-05-05T17:26:08.629Z</news:publication_date>
        <news:title><![CDATA[ARVO 2026: The natural history of thyroid eye disease]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/arvo-2026-gene-therapy-and-optogenetics-show-lasting-vision-improvement-in-retinitis-pigmentosa</loc><lastmod>2026-05-05T16:00:00Z</lastmod><news:news><news:publication_date>2026-05-05T16:00:00Z</news:publication_date>
        <news:title><![CDATA[ARVO 2026: Gene therapy and optogenetics show lasting vision improvement in retinitis pigmentosa]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/arvo-2026-perfusion-pressure-outperforms-bp-and-iop-as-cardiac-predictor</loc><lastmod>2026-05-04T23:30:00Z</lastmod><news:news><news:publication_date>2026-05-04T23:30:00Z</news:publication_date>
        <news:title><![CDATA[ARVO 2026: Perfusion pressure outperforms BP and IOP as cardiac predictor]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/arvo-2026-a-non-invasive-tool-to-study-the-eye-heart-relationship</loc><lastmod>2026-05-04T23:00:00Z</lastmod><news:news><news:publication_date>2026-05-04T23:00:00Z</news:publication_date>
        <news:title><![CDATA[ARVO 2026: A non-invasive tool to study the eye-heart relationship]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/arvo-2026-is-grok-a-valuable-tool-for-patients-</loc><lastmod>2026-05-04T18:31:00Z</lastmod><news:news><news:publication_date>2026-05-04T18:31:00Z</news:publication_date>
        <news:title><![CDATA[ARVO 2026: Is Grok a valuable tool for patients?]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/srinivas-sadda-md-farvo-on-the-impact-of-arvo-and-the-next-generation</loc><lastmod>2026-05-04T15:00:00Z</lastmod><news:news><news:publication_date>2026-05-04T15:00:00Z</news:publication_date>
        <news:title><![CDATA[Srinivas Sadda, MD, FARVO, on the impact of ARVO, and the next generation]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/arvo-2026-integrating-llms-for-community-based-triage-of-red-eye-diseases</loc><lastmod>2026-05-03T22:29:42.007Z</lastmod><news:news><news:publication_date>2026-05-03T22:29:42.007Z</news:publication_date>
        <news:title><![CDATA[ARVO 2026: Integrating LLMs for community-based triage of red eye diseases]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/arvo-2026-truckee-study-analysis</loc><lastmod>2026-05-03T18:01:43.184Z</lastmod><news:news><news:publication_date>2026-05-03T18:01:43.184Z</news:publication_date>
        <news:title><![CDATA[ARVO 2026: TRUCKEE study analysis]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/openai-introduces-chatgpt-for-clinicians</loc><lastmod>2026-04-30T18:17:36.041Z</lastmod><news:news><news:publication_date>2026-04-30T18:17:36.041Z</news:publication_date>
        <news:title><![CDATA[OpenAI introduces ChatGPT for clinicians]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/review-highlights-potential-role-of-vitamin-b-in-amd-prevention-and-progression</loc><lastmod>2026-04-30T18:09:34.428Z</lastmod><news:news><news:publication_date>2026-04-30T18:09:34.428Z</news:publication_date>
        <news:title><![CDATA[Review highlights potential role of vitamin B in AMD prevention and progression]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/neuroop-guru-eye-and-brain-clues-to-antiphospholipid-syndrome</loc><lastmod>2026-04-30T04:00:00Z</lastmod><news:news><news:publication_date>2026-04-30T04:00:00Z</news:publication_date>
        <news:title><![CDATA[NeuroOp Guru: When eye and brain strokes point to antiphospholipid syndrome]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/ocular-therapeutix-enrolls-first-patient-in-sol-x-long-term-extension-trial-for-axpaxli</loc><lastmod>2026-04-29T13:46:21.065Z</lastmod><news:news><news:publication_date>2026-04-29T13:46:21.065Z</news:publication_date>
        <news:title><![CDATA[Ocular Therapeutix enrolls first patient in SOL-X long-term extension trial for AXPAXLI]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/correcting-textile-and-garment-workers-vision-translates-to-billions-for-low-income-countries</loc><lastmod>2026-04-28T12:00:00Z</lastmod><news:news><news:publication_date>2026-04-28T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Correcting textile and garment workers’ vision translates to billions for low-income countries]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/belite-bio-initiates-rolling-nda-submission-for-tinlarebant-in-stargardt-disease-type-1</loc><lastmod>2026-04-27T14:42:21.140Z</lastmod><news:news><news:publication_date>2026-04-27T14:42:21.140Z</news:publication_date>
        <news:title><![CDATA[Belite Bio initiates rolling NDA submission for tinlarebant in Stargardt disease type 1]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/rising-star-introducing-elizabeth-akinsoji-md-mph</loc><lastmod>2026-04-27T10:00:00Z</lastmod><news:news><news:publication_date>2026-04-27T10:00:00Z</news:publication_date>
        <news:title><![CDATA[Rising Star: Introducing Elizabeth Akinsoji, MD, MPH]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/eyecelerator-launches-eye-to-market-web-series-with-uanither-pharmaceuticals-and-ora</loc><lastmod>2026-04-25T10:06:00Z</lastmod><news:news><news:publication_date>2026-04-25T10:06:00Z</news:publication_date>
        <news:title><![CDATA[Eyecelerator launches “Eye to Market” web series with Unither Pharmaceuticals and Ora]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/condor-clinical-trial-brolucizumab-superior-to-panretinal-photocoagulation-for-proliferative-diabetic-retinopathy</loc><lastmod>2026-04-24T13:49:25.052Z</lastmod><news:news><news:publication_date>2026-04-24T13:49:25.052Z</news:publication_date>
        <news:title><![CDATA[CONDOR clinical trial: Brolucizumab superior to panretinal photocoagulation for proliferative diabetic retinopathy]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/safety-and-clinical-implications-of-otx-tki-in-neovascular-amd</loc><lastmod>2026-04-23T17:31:00Z</lastmod><news:news><news:publication_date>2026-04-23T17:31:00Z</news:publication_date>
        <news:title><![CDATA[Safety and Clinical Implications of OTX-TKI in Neovascular AMD]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/sol-1-phase-3-trial-design-efficacy-and-rescue-treatment-outcomes-in-neovascular-amd</loc><lastmod>2026-04-23T17:26:00Z</lastmod><news:news><news:publication_date>2026-04-23T17:26:00Z</news:publication_date>
        <news:title><![CDATA[SOL-1 Phase 3: Trial Design, Efficacy, and Rescue Treatment Outcomes in Neovascular AMD]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/ascrs-2026-neuropathic-corneal-pain-and-the-evolving-ocular-surface-landscape</loc><lastmod>2026-04-21T16:00:00Z</lastmod><news:news><news:publication_date>2026-04-21T16:00:00Z</news:publication_date>
        <news:title><![CDATA[ASCRS 2026: Neuropathic corneal pain and the evolving ocular surface landscape]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/ascrs-2026-marguerite-mcdonald-on-glueless-sutureless-pterygium-surgery-outcomes</loc><lastmod>2026-04-20T18:00:00Z</lastmod><news:news><news:publication_date>2026-04-20T18:00:00Z</news:publication_date>
        <news:title><![CDATA[ASCRS 2026: Marguerite B. McDonald, MD, FACS, on glueless, sutureless pterygium surgery outcomes]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/oculis-completes-final-patient-visit-in-ocs-01-phase-3-trial-in-dme</loc><lastmod>2026-04-20T15:42:24.925Z</lastmod><news:news><news:publication_date>2026-04-20T15:42:24.925Z</news:publication_date>
        <news:title><![CDATA[Oculis completes final patient visit in OCS-01 phase 3 trial in DME]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/smoking-identified-as-significant-risk-factor-for-vision-threatening-ocular-outcomes</loc><lastmod>2026-04-20T12:51:43.622Z</lastmod><news:news><news:publication_date>2026-04-20T12:51:43.622Z</news:publication_date>
        <news:title><![CDATA[Smoking identified as significant risk factor for vision-threatening ocular outcomes]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/dual-sensory-impairment-may-limit-functional-improvement-after-vision-rehab</loc><lastmod>2026-04-20T12:38:40.429Z</lastmod><news:news><news:publication_date>2026-04-20T12:38:40.429Z</news:publication_date>
        <news:title><![CDATA[Dual sensory impairment may limit functional improvement after vision rehab]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/glaukos-epioxa-for-keratoconus-receives-permanent-j-code-effective-july-1-2026</loc><lastmod>2026-04-18T04:00:00Z</lastmod><news:news><news:publication_date>2026-04-18T04:00:00Z</news:publication_date>
        <news:title><![CDATA[Glaukos’ Epioxa for keratoconus receives permanent J-code effective July 1, 2026]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/ascrs-2026-gabriel-quesada-md-on-robotic-femtosecond-laser-for-lasik-flap-creation</loc><lastmod>2026-04-17T18:00:00Z</lastmod><news:news><news:publication_date>2026-04-17T18:00:00Z</news:publication_date>
        <news:title><![CDATA[ASCRS 2026: Gabriel Quesada, MD, on robotic femtosecond laser for LASIK flap creation]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/positive-topline-results-promising-future-for-bimatoprost-drug-pad-iol-system-with-fiaz-zaman-md</loc><lastmod>2026-04-16T21:00:00Z</lastmod><news:news><news:publication_date>2026-04-16T21:00:00Z</news:publication_date>
        <news:title><![CDATA[Positive Topline Results, Promising Future for Bimatoprost Drug Pad-IOL System, With Fiaz Zaman, MD]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/ascrs-2026-eric-d-donnenfeld-md-highlights-early-response-patterns-with-lifitegrast-in-dry-eye</loc><lastmod>2026-04-16T18:00:00Z</lastmod><news:news><news:publication_date>2026-04-16T18:00:00Z</news:publication_date>
        <news:title><![CDATA[ASCRS 2026: Eric D. Donnenfeld, MD, highlights early response patterns with lifitegrast in dry eye]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/modular-shape-changing-iol-for-presbyopia-improves-vision-at-36-months-demonstrates-lasting-effects</loc><lastmod>2026-04-15T18:00:00Z</lastmod><news:news><news:publication_date>2026-04-15T18:00:00Z</news:publication_date>
        <news:title><![CDATA[Modular, Shape-Changing IOL for Presbyopia Improves Vision at 36 Months, Demonstrates Lasting Effects]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/additional-sol-1-analyses-shows-delayed-csft-worsening-with-axpaxli</loc><lastmod>2026-04-15T14:54:27.956Z</lastmod><news:news><news:publication_date>2026-04-15T14:54:27.956Z</news:publication_date>
        <news:title><![CDATA[Additional SOL-1 analyses show delayed CSFT worsening with AXPAXLI]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/ascrs-2026-carlton-yuen-md-on-dual-pump-phaco-fluidics-and-low-endothelial-cell-loss</loc><lastmod>2026-04-14T16:00:00Z</lastmod><news:news><news:publication_date>2026-04-14T16:00:00Z</news:publication_date>
        <news:title><![CDATA[ASCRS 2026: Carlton Yuen, MD, BSc, ABO, on dual-pump phaco fluidics and low endothelial cell loss]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/chemoplaque-therapy-for-retinoblastoma-a-potentially-novel-more-accessible-treatment-approach</loc><lastmod>2026-04-14T14:23:28.899Z</lastmod><news:news><news:publication_date>2026-04-14T14:23:28.899Z</news:publication_date>
        <news:title><![CDATA[Chemoplaque therapy for retinoblastoma: A potentially novel more accessible treatment approach]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/motugivatrep-eye-drops-for-dry-eye-disease-launch-in-japan</loc><lastmod>2026-04-14T11:00:00Z</lastmod><news:news><news:publication_date>2026-04-14T11:00:00Z</news:publication_date>
        <news:title><![CDATA[Motugivatrep eye drops for dry eye disease launch in Japan]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/bridging-borders-in-ophthalmology-reflections-on-international-medical-training</loc><lastmod>2026-04-14T10:00:00Z</lastmod><news:news><news:publication_date>2026-04-14T10:00:00Z</news:publication_date>
        <news:title><![CDATA[Bridging borders in ophthalmology: Reflections on international medical training]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/darovasertib-combination-progression-free-survival-benefit-uveal-melanoma</loc><lastmod>2026-04-13T22:10:03.349Z</lastmod><news:news><news:publication_date>2026-04-13T22:10:03.349Z</news:publication_date>
        <news:title><![CDATA[Darovasertib combination shows progression-free survival benefit in metastatic uveal melanoma]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/ascrs-2026-light-adjustable-lens-outcomes-with-femtosecond-laser-vs-manual-capsulotomy</loc><lastmod>2026-04-13T17:30:00Z</lastmod><news:news><news:publication_date>2026-04-13T17:30:00Z</news:publication_date>
        <news:title><![CDATA[ASCRS 2026: Light Adjustable Lens outcomes with femtosecond laser vs manual capsulotomy]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/eclipse-life-sciences-completes-enrollment-in-bettis-1-phase-2-clinical-trial</loc><lastmod>2026-04-13T14:52:46.994Z</lastmod><news:news><news:publication_date>2026-04-13T14:52:46.994Z</news:publication_date>
        <news:title><![CDATA[Eclipse Life Sciences completes enrollment in BETTIS-1 phase 2 clinical trial]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/management-surgical-outcomes-dry-eye-before-during-after</loc><lastmod>2026-04-12T13:30:00Z</lastmod><news:news><news:publication_date>2026-04-12T13:30:00Z</news:publication_date>
        <news:title><![CDATA[The role of management in surgical outcomes: Treating dry eye before, during, and after]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/first-in-human-technology-enables-real-time-outflow-measurement-during-glaucoma-surgery</loc><lastmod>2026-04-12T10:00:00Z</lastmod><news:news><news:publication_date>2026-04-12T10:00:00Z</news:publication_date>
        <news:title><![CDATA[First-in-human technology enables real-time outflow measurement during glaucoma surgery]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/ascrs-2026-the-emerging-concept-of-tolerance-to-refractive-error-in-iol-designs</loc><lastmod>2026-04-12T04:00:00Z</lastmod><news:news><news:publication_date>2026-04-12T04:00:00Z</news:publication_date>
        <news:title><![CDATA[ASCRS 2026: The emerging concept of tolerance to refractive error in IOL designs]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/premium-iols-complex-eyes-reframing-possible-keratorefractive-surgery</loc><lastmod>2026-04-11T17:30:35.315Z</lastmod><news:news><news:publication_date>2026-04-11T17:30:35.315Z</news:publication_date>
        <news:title><![CDATA[Premium IOLs in complex eyes: Reframing what's possible after keratorefractive surgery]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/insight-cataract-surgeons-ocular-surface-outflow-glaucoma-surgery</loc><lastmod>2026-04-11T13:30:35.315Z</lastmod><news:news><news:publication_date>2026-04-11T13:30:35.315Z</news:publication_date>
        <news:title><![CDATA[Multiple presentations offer insight to cataract surgeons about the ocular surface and outflow in glaucoma surgery]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/ascrs-2026-evolving-approaches-to-glaucoma-surgery-and-complication-management</loc><lastmod>2026-04-11T04:00:00Z</lastmod><news:news><news:publication_date>2026-04-11T04:00:00Z</news:publication_date>
        <news:title><![CDATA[ASCRS 2026: Evolving approaches to glaucoma surgery and complication management]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/inside-the-ascrs-preoperative-ocular-surface-disease-algorithm-key-updates</loc><lastmod>2026-04-10T18:00:00Z</lastmod><news:news><news:publication_date>2026-04-10T18:00:00Z</news:publication_date>
        <news:title><![CDATA[Inside the ASCRS preoperative ocular surface disease algorithm: Key updates]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.ophthalmologytimes.com/view/ascrs-2026-daniel-h-chang-md-outlines-paradigm-for-characterizing-depth-of-field-iols</loc><lastmod>2026-04-10T16:00:00Z</lastmod><news:news><news:publication_date>2026-04-10T16:00:00Z</news:publication_date>
        <news:title><![CDATA[ASCRS 2026: Daniel H. Chang, MD, outlines paradigm for characterizing depth-of-field IOLs]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url></urlset>